Education
About Us
Working with TipRanks
Follow Us
EyePoint Pharmaceuticals Inc (EYPT)
NASDAQ:EYPT
Total Valuation
EyePoint Pharmaceuticals has a market cap or net worth of $1.10B. The enterprise value is $1.02B.
Market Cap$1.10B
Enterprise Value$1.02B
Share Statistics
EyePoint Pharmaceuticals has 83,431,950 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding83,431,950
Owned by Insiders10.89%
Owned by Institutions9.51%
Financial Efficiency
EyePoint Pharmaceuticals’s return on equity (ROE) is -0.76 and return on invested capital (ROIC) is -74.45%.
Return on Equity (ROE)-0.76
Return on Assets (ROA)-0.64
Return on Invested Capital (ROIC)-74.45%
Return on Capital Employed (ROCE)-0.74
Revenue Per Employee190.13K
Profits Per Employee-1.41M
Employee Count165
Asset Turnover0.09
Inventory Turnover1.14
Valuation Ratios
The current PE Ratio of EyePoint Pharmaceuticals is ―. EyePoint Pharmaceuticals’s PEG ratio is -0.16.
PE Ratio―
PS Ratio42.66
PB Ratio4.37
Price to Fair Value4.37
Price to FCF-5.50
Price to Operating Cash Flow-4.56
PEG Ratio-0.16
Income Statement
In the last 12 months, EyePoint Pharmaceuticals had revenue of 31.37M and earned -231.96M in profits. Earnings per share was -3.17.
Revenue31.37M
Gross Profit29.30M
Operating Income-243.43M
Pretax Income-231.68M
Net Income-231.96M
EBITDA-243.43M
Earnings Per Share (EPS)-3.17
Cash Flow
In the last 12 months, operating cash flow was -240.11M and capital expenditures -3.28M, giving a free cash flow of -243.39M billion.
Operating Cash Flow-240.11M
Free Cash Flow-243.39M
Free Cash Flow per Share-2.92
Dividends & Yields
EyePoint Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.83
52-Week Price Change99.10%
50-Day Moving Average15.47
200-Day Moving Average12.99
Relative Strength Index (RSI)34.53
Average Volume (3m)1.73M
Important Dates
EyePoint Pharmaceuticals upcoming earnings date is May 6, 2026, TBA (Confirmed).
Last Earnings DateMar 4, 2026
Next Earnings DateMay 6, 2026
Ex-Dividend Date―
Financial Position
EyePoint Pharmaceuticals as a current ratio of 8.88, with Debt / Equity ratio of 6.79%
Current Ratio8.88
Quick Ratio8.83
Debt to Market Cap0.00
Net Debt to EBITDA0.33
Interest Coverage Ratio7.38K
Taxes
In the past 12 months, EyePoint Pharmaceuticals has paid 279.00K in taxes.
Income Tax279.00K
Effective Tax Rate>-0.01
Enterprise Valuation
EyePoint Pharmaceuticals EV to EBITDA ratio is -5.16, with an EV/FCF ratio of -5.17.
EV to Sales40.08
EV to EBITDA-5.16
EV to Free Cash Flow-5.17
EV to Operating Cash Flow-5.24
Balance Sheet
EyePoint Pharmaceuticals has $306.09M in cash and marketable securities with $20.77M in debt, giving a net cash position of $285.31M billion.
Cash & Marketable Securities$306.09M
Total Debt$20.77M
Net Cash$285.31M
Net Cash Per Share$3.42
Tangible Book Value Per Share$4.18
Margins
Gross margin is 93.41%, with operating margin of -775.98%, and net profit margin of -739.42%.
Gross Margin93.41%
Operating Margin-775.98%
Pretax Margin-738.53%
Net Profit Margin-739.42%
EBITDA Margin-775.98%
EBIT Margin-775.98%
Analyst Forecast
The average price target for EyePoint Pharmaceuticals is $36.60, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$36.60
Price Target Upside177.27% Upside
Analyst ConsensusStrong Buy
Analyst Count10
Revenue Growth Forecast-7.38%
EPS Growth Forecast-49.03%